AU2018330163B2 - Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide - Google Patents

Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide Download PDF

Info

Publication number
AU2018330163B2
AU2018330163B2 AU2018330163A AU2018330163A AU2018330163B2 AU 2018330163 B2 AU2018330163 B2 AU 2018330163B2 AU 2018330163 A AU2018330163 A AU 2018330163A AU 2018330163 A AU2018330163 A AU 2018330163A AU 2018330163 B2 AU2018330163 B2 AU 2018330163B2
Authority
AU
Australia
Prior art keywords
compound
approximately
solvent
polymorph
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2018330163A
Other languages
English (en)
Other versions
AU2018330163A1 (en
Inventor
Michael P. Smolinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atnx Spv LLC
Original Assignee
Atnx Spv LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018330163(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv LLC filed Critical Atnx Spv LLC
Publication of AU2018330163A1 publication Critical patent/AU2018330163A1/en
Application granted granted Critical
Publication of AU2018330163B2 publication Critical patent/AU2018330163B2/en
Priority to AU2023201010A priority Critical patent/AU2023201010B2/en
Assigned to ATNX SPV, LLC reassignment ATNX SPV, LLC Request for Assignment Assignors: Athenex HK Innovative Limited
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018330163A 2017-09-07 2018-09-07 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide Active 2039-02-23 AU2018330163B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023201010A AU2023201010B2 (en) 2017-09-07 2023-02-21 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201010A Division AU2023201010B2 (en) 2017-09-07 2023-02-21 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Publications (2)

Publication Number Publication Date
AU2018330163A1 AU2018330163A1 (en) 2020-03-26
AU2018330163B2 true AU2018330163B2 (en) 2023-02-02

Family

ID=65517772

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018330163A Active 2039-02-23 AU2018330163B2 (en) 2017-09-07 2018-09-07 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
AU2023201010A Active AU2023201010B2 (en) 2017-09-07 2023-02-21 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023201010A Active AU2023201010B2 (en) 2017-09-07 2023-02-21 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Country Status (15)

Country Link
US (4) US10669236B2 (enExample)
EP (1) EP3679016B1 (enExample)
JP (3) JP2020533412A (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN111278808B (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
FI (1) FI3679016T3 (enExample)
IL (1) IL272992A (enExample)
MX (2) MX2020002622A (enExample)
SG (1) SG11202001868RA (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
HUP0400446A2 (hu) * 2001-05-22 2004-09-28 Pfizer Products Inc. Azitromicin kristályformái
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP2008522983A (ja) * 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
DK2041071T3 (da) * 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
BRPI0717554A2 (pt) * 2006-09-28 2013-10-29 Merck & Co Inc Composição farmacêutica, método para tratar câncer e aliviar os efeitos colaterais do inibidor da hdac, e, método de se obter um complexo de quelato inibidor da hdac de metal
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2015069217A1 (en) 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
BR112019018687A2 (pt) 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Also Published As

Publication number Publication date
KR20240119192A (ko) 2024-08-06
US20190071402A1 (en) 2019-03-07
AU2018330163A1 (en) 2020-03-26
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
SG11202001868RA (en) 2020-03-30
KR102691700B1 (ko) 2024-08-02
JP2025131661A (ja) 2025-09-09
MX2023001805A (es) 2023-03-13
JP2023157909A (ja) 2023-10-26
AU2023201010B2 (en) 2024-10-03
US20250115555A1 (en) 2025-04-10
EP3679016B1 (en) 2025-11-05
US20200255380A1 (en) 2020-08-13
CN111278808B (zh) 2024-04-26
TWI815820B (zh) 2023-09-21
WO2019051147A1 (en) 2019-03-14
CA3074831A1 (en) 2019-03-14
RU2020112539A3 (enExample) 2022-04-19
FI3679016T3 (fi) 2025-12-12
CN118439992A (zh) 2024-08-06
US10669236B2 (en) 2020-06-02
CN111278808A (zh) 2020-06-12
MX2020002622A (es) 2020-10-01
US20220098152A1 (en) 2022-03-31
US11230527B2 (en) 2022-01-25
DK3679016T3 (da) 2025-12-15
IL272992A (en) 2020-04-30
AU2023201010A1 (en) 2023-03-23
TW201920160A (zh) 2019-06-01
BR112020004419A2 (pt) 2020-09-08
JP2020533412A (ja) 2020-11-19
RU2020112539A (ru) 2021-10-08
EP3679016A1 (en) 2020-07-15
EP3679016A4 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
AU2023201010B2 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
TWI772424B (zh) 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
AU2022201947B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
AU2019206118B2 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
HK40079038A (en) Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
HK40009119A (en) Crystal of benzofuran derivative free base and preparation method
HK40009119B (en) Crystal of benzofuran derivative free base and preparation method

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ATNX SPV, LLC

Free format text: FORMER OWNER(S): ATHENEX HK INNOVATIVE LIMITED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST AN EXTENSION OF TERM - PHARMACEUTICAL HAS BEEN EXTENDED TO 23 NOV 2024

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ONAKTA TIRBANIBULIN

Filing date: 20240223

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ONAKTA TIRBANIBULIN

Filing date: 20240223

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ONAKTA TIRBANIBULIN

Filing date: 20240223

Extension date: 20390223